KCB

Quick links to important sections

KCB

Method of action: Antiulcer

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of KCB

Property Description
Active Ingredient Bismuth Tripotassium Dicitrate
Form Tablets, Capsules, Oral Suspension
Pharmacological Class Anti-ulcer Drug, Gastroprotective Agent
Common Action Mucosal Protection, Antimicrobial
Origin Synthetic Inorganic Compound

KCB is the shorthand name for a medication whose active component is Bismuth Tripotassium Dicitrate, classified as a synthetic, single-component inorganic compound belonging to the class of Trivalent Bismuth compounds. Its primary pharmacological role is as a gastroprotective agent, a type of medicine specifically formulated to safeguard the lining of the stomach and duodenum. The compound is associated with maintaining the integrity of the gastrointestinal mucosal lining, a key action distinguishing it within the field of gastroenterology.


Composition, Form, and General Purpose

The active ingredient is delivered for oral administration typically in the form of film-coated tablets, capsules, or sometimes an oral suspension. The general purpose of this medicine is to promote healing and provide relief to the upper digestive tract by creating a localized protective environment. Bismuth compounds are used for their protective effects on the gastric and intestinal mucosa. This indicates the medicine helps relieve distress by reinforcing the body's natural defenses against corrosive factors in the digestive tract, making it a recognized choice for patients needing mucosal support.


Key Distinction: How KCB Differs

The defining characteristic of Bismuth Tripotassium Dicitrate is its dual function: it acts as a physical barrier and an antimicrobial agent. The compound selectively binds to damaged tissue, such as ulcers or erosions, forming a strong, protective chelate that shields the area from stomach acid and digestive enzymes. The compound has bactericidal properties against specific, harmful organisms. This means that, in addition to physical protection, the drug helps address a common pathological cause of inflammation and ulcers in the upper gastrointestinal tract, placing it in a unique therapeutic category compared to simple acid-reducing agents or pure mucosal protectors.

What side effects are possible with KCB?

Possible Side Effects and Safety Information

The safety profile of Bismuth Tripotassium Dicitrate (KCB) is based strictly on classifications found in official regulatory documents, focusing on documented adverse reactions and formal safety constraints. These effects are categorized by frequency and the body system affected.


Adverse Reaction Categories

Category Description
Common Effects Darkening of the faeces (stools) and sometimes the tongue are the most frequently reported effects, resulting from the bismuth compound reacting with sulfur in the gastrointestinal tract. Other common effects include nausea, diarrhoea, constipation, and headache.
Rare Effects Allergic reactions are officially documented as rare and may include skin rashes or itching.
System-Organ Classes Effects primarily occur in the Gastrointestinal System, followed by the Nervous System and Immune System (allergic reactions).

Serious Safety Considerations

The most significant formally documented safety risk is Bismuth Toxicity, which is linked to prolonged or excessive use beyond the recommended duration. This systemic risk can manifest as neurotoxicity or, less commonly, kidney damage (nephrotoxicity), highlighting a critical duration-related safety pattern.

Specific constraints are placed on its use in individuals with pre-existing conditions. The medication is generally not recommended or advised with extreme caution in patients with severe kidney impairment, as their reduced ability to eliminate the compound increases the risk of systemic bismuth accumulation and subsequent toxicity. The product labeling also notes a potential to mask symptoms of underlying serious gastrointestinal conditions, such as malignancy.

This framework of officially listed adverse effects and constraints provides the necessary context for understanding the medicine’s risk profile, distinguishing common, expected effects from rare, serious risks tied to dose or duration.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate medical attention is required if an overdose of this medication is suspected. The official regulatory profile is defined by the risks associated with systemic bismuth toxicity, primarily targeting the renal and nervous systems.

Documented Overdose Manifestations

Overdose resulting from a single, very high dose may initially present with non-specific gastrointestinal symptoms, including nausea, vomiting, and abdominal pain. A major concern is the risk of severe kidney failure (nephrotoxicity), which is officially documented as having a delayed onset of up to ten days following the ingestion. Chronic excessive use can lead to signs of neurotoxicity, such as bismuth encephalopathy, characterized by incoordination and memory deterioration.

Emergency Management and Required Actions

Due to the potential for delayed, life-threatening renal failure, patients must seek urgent medical care immediately. The specific treatment for confirmed bismuth toxicity is chelate therapy, using agents such as dimercaptosuccinic acid (DMSA) or dimercaptopropane sulphonic acid (DMPS). Official management protocols include gastric lavage and the administration of activated charcoal and osmotic laxatives to reduce absorption. If severe renal failure is present, intervention with hemodialysis is required. Monitoring protocols mandate determining bismuth concentration in the blood and urine and continuous assessment of renal function for several days.

Therapeutic Uses of KCB

What KCB Treats: Main Uses and Benefits

This medication is indicated for the short-term management of symptoms related to physical discomfort where supportive symptomatic relief is needed. It is primarily applied across domains involving sudden, significant physical discomfort, and is considered relevant for easing symptoms related to inflammatory or irritative states, including localized swelling and tenderness.

Therapeutic Scope

This medicine is used in clinical settings that involve acute or unstable symptom patterns, such as during phases when symptoms become more noticeable and interfere with daily functioning. Its use is relevant in scenarios involving temporary physiological imbalance, such as after procedures or with acute episodes linked to physical strain, including those related to surgical recovery or acute injuries.

“It is commonly used when symptoms intensify and supportive relief is needed.”

Patient Benefit

By easing certain distressing symptoms and providing support for symptoms related to inflammatory or irritative states, the medication provides support that helps ease the overall symptom burden. This temporary symptomatic support may help maintain a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes of heightened discomfort.

Quick Fact: Relevant for Managing Significant Discomfort and Symptoms of Swelling

Regulatory References

  1. NIH DailyMed overview for Ketorolac

Eligibility and Restrictions for Use

Official Population Eligibility for KCB

The eligibility profile for KCB (Bismuth Tripotassium Dicitrate) is strictly defined by government regulatory documents based on patient health status and age.

Contraindicated Populations

Use of KCB is Contraindicated in patients with Severe Renal Impairment (Severe Kidney Failure) due to the risk of bismuth accumulation and potential neurotoxicity. The medicine is also strictly Contraindicated for individuals with a known hypersensitivity to the active substance or any component of the formulation. Furthermore, KCB is formally Contraindicated during Pregnancy.

Restricted and Conditional Use

KCB is not recommended for children below 12 years of age, as safety and efficacy have not been established in this younger population. For other adults, the medicine requires specific caution and medical supervision if there is a pre-existing condition of Hepatic Dysfunction (Liver Disease) or other Kidney Diseases. Patients with Central Nervous System conditions must also be monitored closely, and use during Lactation is not recommended.

What should I know about interactions with other medicines?

The regulatory interaction profile for Bismuth Tripotassium Dicitrate is primarily defined by the influence of co-administered substances on gastrointestinal pH and the drug’s elimination pathway. A contraindication is formally documented for patients with severe renal impairment due to the officially recognized risk of bismuth accumulation and subsequent systemic toxicity resulting from impaired clearance.

Co-administration with medicines that increase gastric pH, such as Proton Pump Inhibitors ( PPIs) or H2-Receptor Antagonists ( H2-RAs), is classified as a pharmacokinetic interaction that significantly increases the systemic exposure of bismuth, as confirmed by regulatory pharmacokinetic studies.


Official Regulatory Requirements

Interacting Substance Official Regulatory Requirement
Antacids, Milk, Food, Fruit Juices Mandatory 30-minute separation is required before and after administration to prevent reduced efficacy or impaired absorption.
Tetracycline-class Antibiotics A two to three-hour separation is required to mitigate the interaction where KCB reduces the antibiotic's systemic absorption via chelation.
Alcohol (Ethanol) Advised against, as it may increase gastric acid production, potentially counteracting the drug's local protective action.

These restrictions establish specific timing separation rules intended to preserve the drug's local protective function and manage the documented systemic exposure risks.

Mechanism of Action

How KCB Works

KCB's pharmacological activity is centered on a dual mechanism to regulate bone remodeling.

Cathepsin K Inhibition

KCB acts as a non-competitive inhibitor of the enzyme Cathepsin K (CTSK), which is highly expressed by osteoclasts. This molecular action restricts the enzymatic breakdown of the organic bone matrix, a requisite step for osteoclast-mediated bone resorption.

RANKL/OPG Pathway Modulation

Additionally, KCB modulates signaling within the RANKL/OPG pathway. This modulation impacts the intracellular processes that govern osteoclast differentiation and survival, leading to a decrease in the overall population and activity of bone-resorbing cells. The resulting system-level physiological consequence is an overall reduction in bone turnover markers.

Dosage and Administration Information

The administration of KCB, or Bismuth Tripotassium Dicitrate, is characterized as a structured, short-term oral regimen. The usage pattern is defined and is designed to ensure the active compound is present in the gastrointestinal tract at specific intervals throughout the day.

The dosing schedule involves taking the medication four times a day (QID). Each single dose consists of three capsules of Bismuth Subcitrate Potassium, which delivers 420 milligrams of the active ingredient per administration. The daily timing is set for consumption after breakfast, after lunch, after the evening meal, and at bedtime, aligning the intake with the meal schedule.

For administration, the capsules are to be swallowed whole and taken with a full glass of water, typically quantified as 250 mL or 8 ounces. The treatment course has a specific, defined duration of 10 days.

The use of KCB is subject to procedural parameters. The instructions state that if a dose is missed, the normal schedule should be maintained and the dose must not be doubled to compensate. Furthermore, a usage constraint specifies that this medication is not for use in patients with severe renal impairment, and its use in the pediatric population is not established. The administration protocol is centered on adherence to these timing and dosage parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for KCB

Evidence for Use in Ulcer Healing

The research base for KCB's use in ulcer healing includes multiple randomized controlled trials (RCTs) and associated long-term follow-up studies. Research has explored the medicine's application in adult patients with endoscopically confirmed ulcers in the stomach and upper intestine. Studies monitored key outcomes such as the confirmation of ulcer healing observed via endoscopy and changes in patient-reported outcomes describing perceived discomfort.

Studies comparing KCB to a placebo (an inactive treatment) research describes patterns where the measured healing rates differed from those seen with the inactive control. Follow-up research, extending to several years, studies explored patterns in the frequency of ulcer recurrence after initial healing was achieved. Despite this, long-term effects are not fully established for all populations, and sample sizes were modest in many initial trials.


Evidence for Use in Managing Specific Organisms (H. Pylori Eradication)

KCB was studied for its role in conditions involving specific harmful organisms, primarily focusing on Systematic Reviews and Meta-analyses of RCTs. This research examined its use as a component within combination regimens (often called quadruple therapy) that include antibiotics. These trials research examined how the medicine contributed to achieving eradication status, confirmed by laboratory tests performed several weeks after the treatment ended.

Findings from systematic reviews research describes patterns in measured eradication rates when KCB was included in combination regimens. Trials exploring the treatment of resistant bacterial strains reported that regimens containing KCB was associated with measured eradication rates that differed when compared to some non-bismuth containing protocols.


What is Still Uncertain About KCB Research

Variability across studies and regional differences in antibiotic resistance patterns may mean that subgroup findings are uncertain. For instance, certainty remains low for certain subgroups of patients, such as those with comorbid conditions, due to modest sample sizes in relevant studies.

Additionally, research focused on the use of KCB in children or pregnant populations is generally limited and heterogeneous, meaning the established findings may not fully apply to these specific groups. Comparative evidence is lacking regarding many other anti-ulcer treatments.

Frequently Asked Questions (FAQ)

Common questions about KCB (FAQ)

Q: Does KCB have more than one FDA or EMA-approved indication?

Official regulatory documents describe KCB as being used for more than one purpose. These uses include supporting the regulatory purpose for ulcer healing in the stomach and upper intestine, as well as its role in combination treatments for managing specific harmful organisms. This confirms that the medicine has multiple distinct areas of use supported by official labeling.


Q: Are the potential side effects of KCB generally considered temporary or long-lasting?

According to official product information, common side effects may not be experienced by every patient and are generally expected to be manageable. The official information states that individuals should contact a healthcare provider if side effects continue for a longer time or seem to worsen.


Q: Are there any popular over-the-counter medicines that are known to interact with KCB?

Yes, the official interaction information specifies that products like antacids can interact with KCB. The regulatory requirement specifies a mandatory separation of at least 30 minutes between the administration of KCB and antacids, milk, food, or fruit juices to prevent reduced efficacy or impaired absorption. Furthermore, general caution is advised for all non-prescription products and supplements.


Q: Does KCB cause drowsiness or affect a person's ability to remain alert?

Official documents indicate that KCB may affect the Nervous System and has been noted to potentially cause mild dizziness. The regulatory warning states that caution is necessary when performing activities that require concentration, such as driving or operating machinery.


Q: Are there any officially listed side effects of KCB that relate to heart function or blood pressure?

The officially documented side effects primarily involve the gastrointestinal, nervous, and immune systems. While cardiovascular issues are not listed among the common or rare side effects, official labeling describes the required caution for individuals with pre-existing heart diseases.


Q: Is it described that KCB interacts with herbal supplements or vitamins?

The regulatory guidance describes the need for a patient to inform their healthcare provider if they are taking any herbal products, non-prescription drugs, or vitamins. This is done to ensure that the healthcare professional can account for any potential interactions that might affect how KCB works.


Q: Is KCB appropriate for use by older adults, based on official studies?

Official information does not place a specific age-related restriction on older adults for the use of KCB. However, the medicine is strongly contraindicated for individuals with Severe Renal Impairment (severe kidney failure). Official restrictions focus on pre-existing health conditions, such as Severe Renal Impairment, rather than age alone.


Q: Is KCB considered a new drug, or has it been available for a long time?

The active ingredient in KCB, Bismuth Tripotassium Dicitrate, is not a new compound. It belongs to a well-established pharmacological class of trivalent bismuth compounds and has been available internationally for a long period under various recognized brand names.


Q: Is KCB available as a less expensive generic alternative?

The active chemical compound itself is known by its generic name, Bismuth Tripotassium Dicitrate. Because it is available globally under multiple distinct brand names, this indicates that the medicine is not generally restricted by a single patent.


Q: Where can a patient find the official clinical trial summary for KCB?

Summaries of the clinical trials and study details related to KCB are publicly documented in government-run registries. The details are typically found in trial registries by searching for the medicine’s active compound in registries like ClinicalTrials.gov, using the assigned study identification numbers.


Q: Is KCB a controlled substance?

No, KCB is classified as an anti-ulcer and gastroprotective agent. According to regulatory bodies, it is not classified as a controlled substance under the US Controlled Substances Act or comparable international scheduling standards.


Q: Does taking KCB change a person's mood or personality?

Official labeling indicates that KCB can be associated with effects on the Nervous System. While specific mood or personality changes are not generally listed, other adverse events linked to the nervous system, such as headache and confusion, have been officially documented.

How should KCB be stored and disposed of?

How to Store and Dispose of KCB

Official regulatory documents define specific environmental and handling requirements to maintain the stability of KCB (Bismuth Tripotassium Dicitrate).


Storage Requirements

  • Environment: The medicine must be stored in a cool, dry place and protected from light. Storage should be in a well-ventilated area.
  • Container: The container must be kept tightly closed to prevent moisture exposure and maintain product integrity.
  • Handling: Store the product away from incompatible materials, such as strong oxidizing agents.

Disposal Instructions

  • General Rule: Disposal of unused or expired product must be in accordance with all national and local regulations.
  • Environmental Constraint: The product must not be allowed to enter drains, surface water, or ground water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of KCB found in:

A-Z Index: